Fate Therapeutics Inc (FATE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.74M
Last updated: Nov 17, 2026 at 11:06 AM ET
Fate Therapeutics Inc (FATE) Stock Forecast
Analysts expect Fate Therapeutics (FATE) to earn -$0.99 per share in the fiscal year ending Dec 31, 2026, on revenue of $3.58M. Of 11 analysts, 5 rate the stock Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 4 estimates for the fiscal year ending Dec 31, 2026 were revised up and 2 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 2.45, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 45% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 9.1% |
| Buy | 4 | 36.4% |
| Hold | 6 | 54.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus is unchanged and revenue estimates rise 17.9%.
- Fiscal year ending Dec 31, 2026
- -$0.99
- EPS consensus, revenue $3.58M
- Fiscal year ending Dec 31, 2027
- -$0.99
- EPS consensus, revenue $4.22M
- Next report
- Feb 24, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.99 | -$1.02 to -$0.88 | 7 | $3.58M | $3.38M to $4.38M | 6 |
| Dec 31, 2027 | -$0.99 | -$1.30 to -$0.69 | 8 | $4.22M | N/A | 9 |
Quarterly Estimates
The EPS consensus falls from -$0.25 for the quarter ending Dec 31, 2026 to -$0.27 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.25 | -$0.27 to -$0.16 | 14 | $849997 | N/A | 14 |
| Mar 31, 2027 | -$0.27 | -$0.33 to -$0.23 | 5 | $671430 | N/A | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 9 upward and 4 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 4 | 2 |
| Fiscal year ending Dec 31, 2027 | 3 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$1.04.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.99 | -$1.02 | -$1.02 | -$1.02 | -$1.04 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.99 | -$0.97 | -$0.97 | -$0.97 | -$0.99 | N/A |
| Quarter ending Mar 31, 2027 | -$0.27 | -$0.28 | -$0.28 | -$0.28 | -$0.28 | N/A |
Frequently Asked Questions About FATE
What is the FATE stock forecast?
Consensus analyst estimates put Fate Therapeutics's EPS at -$0.99 for the fiscal year ending Dec 31, 2026, on revenue of $3.58M. The consensus rating from 11 analysts is Buy.
How do analysts rate FATE stock?
Of 11 analysts covering Fate Therapeutics, 1 rates it Strong Buy, 4 Buy, 6 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from FATE next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.99, with estimates from -$1.02 to -$0.88 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.99, with estimates from -$1.30 to -$0.69 from 8 analysts.
What revenue do analysts expect from Fate Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $3.58M, with estimates from $3.38M to $4.38M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $4.22M.
How many analysts cover FATE?
11 analysts rate Fate Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
FATE pages: Overview, Earnings, Forecast, Financials, Competitors